17:02 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $500M-$510M, consensus $506.3M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact